Methods of obtaining tumor-specific t cell receptors
AssigneesSYZ Cell Therapy Co., HRYZ (Shenzhen) Biotech Co.
InventorsXiangjun ZHOU, Yanyan HAN, Xiaoling LIANG, Xihe CHEN
Life of this patent
Estimating the term…
Abstract
Provided methods of obtaining a plurality of T cell receptors specifically recognizing a target tumor antigen peptide from an individual that has clinically benefitted from an immunotherapy, such as Multiple Antigen Specific Cell Therapy. Also provided tumor-specific TCRs, engineered immune cells expressing the TCRs and methods of treating a disease using the engineered immune cells.
Claims22
A method of obtaining a plurality of T cell receptors (TCRs) specifically recognizing a target tumor antigen peptide, comprising:
- a) a first co-culturing step comprising co-culturing a first population of dendritic cells (DCs) loaded with the target tumor antigen peptide with a population of T cells from an individual to obtain a first co-culture;
- b) an enrichment step comprising subjecting the first co-culture to an enrichment process to obtain enriched activated T cells;
- c) a second co-culturing step comprising co-culturing the enriched activated T cells with a second population of DCs loaded with the target tumor antigen peptide to obtain a population of tumor antigen-specific T cells, wherein at least about 10% of the tumor antigen-specific T cells specifically responds to the target tumor antigen peptide;
- and
- d) a sequencing step, comprising subjecting the tumor antigen-specific T cells to next-generation sequencing to identify a plurality of pairs of genes encoding TCRα and TCRβ, thereby providing the plurality of T cell receptors based on paired genes encoding TCRα and TCRβ;
- wherein the individual has clinically benefitted from a Multiple Antigen Specific Cell Therapy (MASCT) comprising administering to the individual an effective amount of activated T cells prepared by co-culturing a population of T cells with a population of dendritic cells loaded with a plurality of tumor antigen peptides comprising the target tumor antigen peptide.
2-34. (canceled)
A tumor-specific TCR comprising:
- (a) a TCRα chain comprising a complementary determining region (CDR) 3 having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs:
- 4, 10, and 16;
- and a TCRβ chain comprising a CDR3 comprising an amino acid sequence having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs:
- 7, 13, and 19;
- (b) a TCRα chain comprising a complementary determining region (CDR) 3 having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs:
- 22, 28, 34, 40, 46, and 52;
- and a TCRβ chain comprising a CDR3 comprising an amino acid sequence having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs:
- 7, 13, 19, 25, 31, 37, 43, 49, and 55;
- or
- (c) a TCRα chain comprising a complementary determining region (CDR) 3 having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs:
- 58, 64, 70, 76, 87 and 93;
- and a TCRβ chain comprising a CDR3 comprising an amino acid sequence having at least about 90% sequence identity to any one of the amino acid sequences of SEQ ID NOs:
- 61, 67, 73, 79, 90 and 96.
A tumor-specific TCR comprising:
- (a) a TCRα chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs:
- 5, 11 and 17, and a TCRβ chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs:
- 8, 14 and 20;
- (b) a TCRα chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs:
- 23, 29, 35, 41, 47 and 53, and a TCRβ chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs:
- 26, 32, 38, 44, 50 and 56;
- or
- (c) a TCRα chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs:
- 59, 65, 71, 77, 88 and 94, and a TCRβ chain comprising CDRs of any one of the amino acid sequences of SEQ ID NOs:
- 62, 68, 74, 80, 91 and 97.
(canceled)
An engineered immune cell comprising the tumor-specific TCR of 36.
(canceled)
Dependencies are inferred from the claim text.